Osimertinib Cancer Treatment

Debate between Lord Bruce of Bennachie and Lord Bethell

Tuesday 18th May 2021 Lords Chamber

[Lord Bethell (Con)]

My Lords, I have met with industry on this matter for the past 18 months. I am afraid that the message I get from it is not of the alarmist kind that the noble Lord described—quite the opposite. I pay tribute to the industry for its enormously collaborative sense of partnership and I really do not believe that there is any threat of the kind that the noble Lord described.

[Lord Bruce of Bennachie (LD) [V]]

Speaking from Aberdeenshire, I know that drug approval can differ between Scotland and England. Now that we have left the EU, is it not inevitable that there will be differences in drug approval and timings from time to time? What are the Government doing, having signed the agreement, to opt out of the EMA and negotiate an arrangement that minimises disruption but does not pretend that it cannot happen because that is what they signed up for?

[Lord Bethell (Con)]

My Lords, there will be an occasional moment when there are slight differences between the EMA and MHRA; we are not anticipating them to be huge and, in this case, we are anticipating them to be a matter of weeks while one approval does not quite overlap with another. The UK Government and the MHRA are working closely with the Northern Ireland Executive and all relevant stakeholders to ensure that the supply of medicines to all UK patients, including those in Northern Ireland, remains smooth, seamless and efficient.